Dyne Therapeutics logo

Dyne TherapeuticsNASDAQ: DYN

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

17 September 2020

Next earnings report:

05 March 2025

Last dividends:

N/A

Next dividends:

N/A
$3.05 B
-35%vs. 3y high
85%vs. sector
-vs. 3y high
-vs. sector
-82%vs. 3y high
77%vs. sector
-vs. 3y high
-vs. sector

Price

pre-market | 62 min ago
$29.99$0.00(0.00%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

DYN Latest News

Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases
seekingalpha.com11 November 2024 Sentiment: POSITIVE

Dyne Therapeutics, Inc. develops treatments for muscle diseases using its FORCE platform, with promising candidates DYNE-101 and DYNE-251 targeting DM1 and DMD, respectively. DYNE-251 shows significant improvement over Sarepta's Eteplirsen in Phase 1/2 trials, potentially accelerating approval and boosting DYN's stock. Key risks include executive reshuffling and potential hidden issues with IP, but current data and market potential make DYN attractive for speculative investors.

Dyne Therapeutics to Present at Upcoming Investor Conferences
globenewswire.com07 November 2024 Sentiment: POSITIVE

WALTHAM, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc.  (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to present at the following upcoming investor conferences:

Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And Affected Shareholders Are Urged To Contact The Schall Law Firm
accesswire.com03 November 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / November 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
prnewswire.com02 November 2024 Sentiment: NEGATIVE

NEW YORK , Nov. 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or the "Company") (NASDAQ: DYN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
accesswire.com31 October 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / October 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or the "Company") (NASDAQ:DYN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

The Schall Law Firm Encourages Investors To Join An Inquiry Into Dyne Therapeutics, Inc. For Securities Law Violations
accesswire.com27 October 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / October 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And Shareholders With Losses Are Urged To Contact The Schall Law Firm
accesswire.com26 October 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / October 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
prnewswire.com25 October 2024 Sentiment: NEGATIVE

NEW YORK , Oct. 25, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or the "Company") (NASDAQ: DYN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And Impacted Shareholders Are Urged To Contact The Schall Law Firm
accesswire.com20 October 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / October 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Encourages Investor Participation In An Inquiry Into Dyne Therapeutics, Inc. For Securities Law Violations
accesswire.com19 October 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / October 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

What type of business is Dyne Therapeutics?

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

What sector is Dyne Therapeutics in?

Dyne Therapeutics is in the Healthcare sector

What industry is Dyne Therapeutics in?

Dyne Therapeutics is in the Biotechnology industry

What country is Dyne Therapeutics from?

Dyne Therapeutics is headquartered in United States

When did Dyne Therapeutics go public?

Dyne Therapeutics initial public offering (IPO) was on 17 September 2020

What is Dyne Therapeutics website?

https://www.dyne-tx.com

Is Dyne Therapeutics in the S&P 500?

No, Dyne Therapeutics is not included in the S&P 500 index

Is Dyne Therapeutics in the NASDAQ 100?

No, Dyne Therapeutics is not included in the NASDAQ 100 index

Is Dyne Therapeutics in the Dow Jones?

No, Dyne Therapeutics is not included in the Dow Jones index

When was Dyne Therapeutics the previous earnings report?

No data

When does Dyne Therapeutics earnings report?

The next expected earnings date for Dyne Therapeutics is 05 March 2025